A nasal spray made with the compound called INNA-051 managed to stop the replication of the coronavirus 96% in laboratory tests. The substance was created to contain the spread of the common flu virus and colds, but has not yet been proven effective for that purpose.
INNA-051 was developed by the Australian Ena Respiratory and has molecules that activate the TLR2 and TLR6 receptors in the cells of the nose and throat. As a result, there is an increase in immunity in these regions.
The test, carried out on animals, was conducted by Miles Carroll, deputy director and head of research at Porton Down of Public Health England, UK.
Ena Respiratory says it can produce nasal spray in large quantities quickly. But first, it will be necessary to check whether the positive containment effects of the new coronavirus observed in ferrets will be replicated in humans or not.
The work, signed by 24 researchers, was published in the repository of scientific studies bioRxiv, but it still needs peer review – a procedure for validating the scientific community by researchers not linked to the study.
Testing of the Ena Respiratory nasal spray is scheduled to take place over the next four months.
In Brazil, the University of São Paulo (USP) is preparing a nasal spray vaccine against the new coronavirus. If all goes well in the tests, the Brazilian vaccine will be available as early as 2021.